文献速递急性肾损伤血液净化与透析

接受分子吸附再循环系统治疗后的肾脏结局

Kidney Outcomes Following Utilization of Molecular Adsorbent Recirculating System.
PubMed 文献 · Kidney Int Rep · 2023-08-12

本研究纳入2014年1月至2020年12月在一家三级中心启动MARS治疗的49例患者,评估治疗指征、移植、CKRT、肾功能恢复和死亡。结果显示59%患者需同期CKRT,CKRT组住院死亡率41% vs 非CKRT组10%(RR 4.15,95%CI 1.04–16.52,P=0.044),1年死亡率CKRT组59% vs 非CKRT组25%(未调整RR 2.92,95%CI 1.08–7.94,P=0.035)。

要点

  • MARS患者中59%(29/49)需同期CKRT,肝性脑病是最常见启动指征(55%)。
  • CKRT组住院死亡率41%(12/29)vs 非CKRT组10%(2/20),RR 4.15(95%CI 1.04–16.52,P=0.044)。
  • CKRT组1年死亡率59%(17/29)vs 非CKRT组25%(5/20),未调整RR 2.92(95%CI 1.08–7.94,P=0.035)。

核心结论

  • 需要MARS治疗的患者常合并AKI而需同期CKRT,且与较高的住院和1年死亡率相关。

研究设计与样本

  • 单中心队列研究,纳入2014年1月至2020年12月在一家三级中心启动MARS治疗的患者49例(67%女性,75%白人)。

主要发现

  • 49例中29例(59%)需同期CKRT,肝性脑病为最常见MARS启动指征(55%)。
  • 住院死亡率CKRT组41%(12/29)vs 非CKRT组10%(2/20),RR 4.15(95%CI 1.04–16.52,P=0.044);校正预设患者特征后仍持续(所有RR≥3.76,所有P≤0.060)。
  • MARS启动后1年死亡率总体较高,CKRT组最高:59%(17/29)vs 非CKRT组25%(5/20),未调整RR 2.92(95%CI 1.08–7.94,P=0.035)。
  • MARS后接受肝移植者占41%(20/49)。
  • CKRT后39%(9/29)患者在出院前肾功能恢复。

临床怎么用

  • 原文未报告临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Molecular adsorbent recirculating system (MARS) is an extracorporeal system combining conventional veno-venous hemodiafiltration and adsorption to provide rescue support in fulminant hepatic failure. Acute kidney injury (AKI) is common in patients with hepatic failure warranting continuous kidney replacement therapy (CKRT). Our primary aim was to characterize a cohort of patients who received MARS therapy and examine kidney events given the current paucity of available data. METHODS: Patients initiating MARS in a tertiary care setting from January 2014 through December 2020 were assessed for treatment indications, transplantation, CKRT, kidney recovery, and death. Data was collected using the REDCAP software. RESULTS: A total of 49 patients (67% female; 75% White) received MARS therapy with 29 patients (59%) requiring concomitant CKRT. Hepatic encephalopathy (HE) was the most common indication for MARS initiation (55%). In-hospital mortality was 41% (12/29) among patients who received CKRT versus 10% (2/20) among those not requiring CKRT (relative risk [RR] 4.15, 95% confidence interval [CI] 1.04 to 16.52, P = 0.044); this persisted following adjustment for prespecified patient characteristics (all RR ≥ 3.76, all P ≤ 0.060). One-year mortality post-MARS initiation was high overall but highest among the CKRT group (59% [17/29] vs. 25% [5/20] unadjusted RR 2.92, 95% CI 1.08 to 7.94, P = 0.035). Liver transplant after MARS occurred in 41% of patients (20/49). After CKRT, 39% of patients (9/29) recovered kidney function prior to hospital discharge. CONCLUSIONS: Patients requiring MARS frequently have AKI warranting the use of concomitant CKRT, which is associated with a high rate of in-hospital and 1-year mortality.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Trautman CL, Khan M, Baker LW, et al. Kidney Outcomes Following Utilization of Molecular Adsorbent Recirculating System. Kidney Int Rep. 2023. PMID: 37850016. doi:10.1016/j.ekir.2023.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。